Clinical trialPhase 2Unknown
A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer
A Phase II Clinical Trial of the Safety and Efficacy of Fruquintinib in Advanced Pancreatic Cancer Patients Who Failed Second-line Gemcitabine or 5-FU Based Chemotherapy
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Unknown
- Study type
- Interventional
- Start
- February 2022
- Expected end
- February 2024
- Enrollment
- 32 participants
- Sites
- 1
- Primary outcomes
- progression free survival (PFS)
- Sponsor
- Other
- Results posted
- No
- Last update
- 25 February 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 4
- BackgroundEffect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer:… DOI 10.1001/jama.2018.7855↗
- BackgroundA Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial gro… DOI 10.1007/s00280-016-3069-8↗
- BackgroundRandomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receivi… DOI 10.1016/j.ejca.2013.04.002↗
- BackgroundVEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study … DOI 10.1093/annonc/mds134↗